Short-Term Safety of Booster Immunization with BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers

Yael Paran*, Esther Saiag, Avishay Spitzer, Yoel Angel, Michal Yakubovsky, Hagit Padova, Ronen Ben-Ami, Ilana Goldinger, Ronni Gamzu, Eli Sprecher, David Zeltser, Oryan Henig

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

This study demonstrated a favorable short-Term safety profile after a third dose of the BNT162b2 vaccine among healthcare workers (HCWs). There were more frequent local reactions and less systemic reactions compared to the second dose. The HCWs who reported reactions had higher prebooster titer of anti-S1 antibodies compared to those who reported no reactions.

Original languageEnglish
Article numberofab656
JournalOpen Forum Infectious Diseases
Volume9
Issue number3
DOIs
StatePublished - Mar 2022

Keywords

  • BNT162b2
  • COVID-19
  • antibodies
  • booster
  • side-effects

Fingerprint

Dive into the research topics of 'Short-Term Safety of Booster Immunization with BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers'. Together they form a unique fingerprint.

Cite this